Calliditas Therapeutics Balance Sheet Health
Financial Health criteria checks 4/6
Calliditas Therapeutics has a total shareholder equity of SEK334.8M and total debt of SEK939.5M, which brings its debt-to-equity ratio to 280.6%. Its total assets and total liabilities are SEK1.9B and SEK1.5B respectively.
Key information
280.6%
Debt to equity ratio
kr939.51m
Debt
| Interest coverage ratio | n/a |
| Cash | kr973.73m |
| Equity | kr334.81m |
| Total liabilities | kr1.52b |
| Total assets | kr1.86b |
Recent financial health updates
Health Check: How Prudently Does Calliditas Therapeutics (STO:CALTX) Use Debt?
Jan 12
Is Calliditas Therapeutics (STO:CALTX) Weighed On By Its Debt Load?
Sep 22Is Calliditas Therapeutics (STO:CALTX) Using Debt Sensibly?
Feb 24Health Check: How Prudently Does Calliditas Therapeutics (STO:CALTX) Use Debt?
Nov 25Is Calliditas Therapeutics (STO:CALTX) Using Too Much Debt?
Aug 03Is Calliditas Therapeutics (STO:CALTX) A Risky Investment?
Apr 24Recent updates
Analysts Have Lowered Expectations For Calliditas Therapeutics AB (publ) (STO:CALTX) After Its Latest Results
Feb 24Health Check: How Prudently Does Calliditas Therapeutics (STO:CALTX) Use Debt?
Jan 12Market Might Still Lack Some Conviction On Calliditas Therapeutics AB (publ) (STO:CALTX) Even After 42% Share Price Boost
Dec 22Is Calliditas Therapeutics (STO:CALTX) Weighed On By Its Debt Load?
Sep 22What You Need To Know About The Calliditas Therapeutics AB (publ) (STO:CALTX) Analyst Downgrade Today
Aug 19Investors Don't See Light At End Of Calliditas Therapeutics AB (publ)'s (STO:CALTX) Tunnel And Push Stock Down 26%
May 26Is Calliditas Therapeutics (STO:CALTX) Using Debt Sensibly?
Feb 24Health Check: How Prudently Does Calliditas Therapeutics (STO:CALTX) Use Debt?
Nov 25Calliditas Therapeutics AB (publ) (STO:CALTX) Analysts Just Slashed This Year's Revenue Estimates By 19%
Aug 24Is Calliditas Therapeutics (STO:CALTX) Using Too Much Debt?
Aug 03Is Calliditas Therapeutics (STO:CALTX) A Risky Investment?
Apr 24Need To Know: The Consensus Just Cut Its Calliditas Therapeutics AB (publ) (STO:CALTX) Estimates For 2022
Mar 19Analysts' Revenue Estimates For Calliditas Therapeutics AB (publ) (STO:CALTX) Are Surging Higher
Feb 28Calliditas Therapeutics AB (publ) (STO:CALTX) Analysts Are Pretty Bullish On The Stock After Recent Results
Feb 27Financial Position Analysis
Short Term Liabilities: CALTX's short term assets (SEK1.3B) exceed its short term liabilities (SEK407.1M).
Long Term Liabilities: CALTX's short term assets (SEK1.3B) exceed its long term liabilities (SEK1.1B).
Debt to Equity History and Analysis
Debt Level: CALTX has more cash than its total debt.
Reducing Debt: CALTX's debt to equity ratio has increased from 0% to 280.6% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CALTX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if CALTX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.